Journal article
Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia
Agus Setyadi, Eggi Arguni, Enny Kenangalem, Afdhal Hasanuddin, Daniel A Lampah, Kamala Thriemer, Nicholas M Anstey, Paulus Sugiarto, Julie A Simpson, Ric N Price, Nicholas M Douglas, Jeanne R Poespoprodjo
MALARIA JOURNAL | BMC | Published : 2019
Abstract
BACKGROUND: Primaquine (PQ) prevents relapses of vivax malaria but may induce severe haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Data on the safety of primaquine in infants are limited. METHODS: A retrospective, hospital-based cohort study of infants aged 1-12 months with vivax malaria was carried out in Timika, Papua province, Indonesia. Risks of admission, death and severe haematological outcomes within 30 days of first presentation were compared between infants who did and did not receive primaquine. Infants were not tested routinely for G6PD deficiency as per local guidelines. RESULTS: Between 2004 and 2013, 4078 infants presented to the hospital for the fi..
View full abstractRelated Projects (2)
Grants
Awarded by Wellcome Trust
Awarded by Australian National Health and Medical Research Council
Awarded by National Health and Medical Research Council of Australia
Awarded by Australian Centre for Research Excellence on Malaria Elimination - NHMRC
Funding Acknowledgements
The study was funded by the Wellcome Trust (Training Fellowship in Tropical Medicine awarded to JRP 099875), and the Australian National Health and Medical Research Council (Senior Research Fellowship to JAS (1104975) and Senior Principal Research Fellowship to NMA (1135820). The Timika Research Facility and Papuan Health and Community Development Foundation were supported by the Department of Foreign Affairs and Trade and the National Health and Medical Research Council of Australia (Program Grant 1037304). This work was supported by the Australian Centre for Research Excellence on Malaria Elimination, funded by the NHMRC (1134989).